The rollout centers on JanusMatrix 2.1, which utilizes AI to weight human epitope cross-conservation against prevalence data. By refining how the platform interprets immune tolerance, EpiVax provides a more granular view of therapeutic epitopes. This advancement underpins the new JanusMatrix-Adjusted EpiMatrix score, or JAX, which merges tolerance potential directly into traditional risk assessments to offer a biologically-informed density profile of effector epitopes.
Alongside these updates, the company released its ADA 2.2 model. This iteration shifts beyond simple epitope-based measures, incorporating biophysical attributes and specific mode-of-action criteria. Trained on a diverse clinical dataset of monoclonal antibodies, the model shows a tighter correlation between digital predictions and observed clinical outcomes. These enhancements arrive as the FDA increasingly encourages the adoption of human-relevant New Approach Methodologies, positioning the platform as a tool to protect asset value and streamline the transition from development to regulatory submission.
Comments (0)
No comments yet. Be the first!